


CANCER RESEARCH TECHNOLOGY

ADVANCING DISCOVERIES TO BEAT CANCER

WHAT WE ACHIEVED IN 2015/16

TRANSLATION OF PROMISING SCIENTIFIC RESEARCH



3 NEW COMPANIES formed this year, taking our total number of spin-out companies to **31**



36 NEW PROJECTS entered our portfolio this year, taking our current portfolio to **170** projects in development

260



PRINCIPAL INVESTIGATORS engaged with to progress their research



31 MAJOR LICENCE OR COLLABORATION DEALS completed and a further **35** other agreements completed

BUILT INNOVATIVE ALLIANCES IN OUR DRUG DISCOVERY LABS



3RD PROJECT FROM OUR DEUBIQUITINASE ALLIANCE with Forma Therapeutics entered lead optimisation, advancing towards clinical trials

ALLIANCE ESTABLISHED with Merck KGaA to explore target validation and assay build within the Hippo pathway, one that is often de-regulated in cancers of high unmet need

DELIVERED PATIENT BENEFIT

38



TOTAL NUMBER OF DRUGS IN CLINIC



8 LICENCES COMPLETED for the IBIS breast cancer risk assessment tool this year, taking the total number of licences to **17**



A 2ND PRODUCT ADVANCED TO CLINICAL TRIALS from our CEA antibody programme licensed to Roche



NICE RECOMMENDATION RECEIVED

for Lynparza, a product in our development pipeline, and it advanced to phase 3 clinical trials across multiple indications

DROVE INVESTMENT TO PROGRESS CANCER RESEARCH

£185M

ADDITIONAL INVESTMENT RAISED BY CRT SPIN-OUT COMPANIES



£29M

LEVERAGED IN INDUSTRIAL AND EXTERNAL GRANT SUPPORT FOR CRUK RESEARCHERS



£20M

PROFIT FROM CRT RETURNED TO CRUK TO FUND FURTHER RESEARCH

Values based on data from 1st April 2015 – 31st March 2016

cancertechnology.com



CANCER RESEARCH TECHNOLOGY